One in eight women will be diagnosed with breast cancer in her lifetime.
Proper testing will assist physicians in diagnosing and treating a current cancer, predicting recurrence, and determining hereditary status for their patients.
Propelling Research and Knowledge
The BRCA1 and BRCA2 Mutation Database provides information on BRCA1 and BRCA2 gene mutations and their impact on risk of developing breast cancer, ovarian cancer, and certain other cancers.
This database may be used by anyone at no cost.
To view the database, visit: http://arup.utah.edu/database/BRCA/
Breast Cancer Subtypes
It is important to know the subtype of breast cancer in women for guiding treatment and predicting survival.
About 5-10% of all breast cancers are thought to be hereditary. If hereditary breast cancer is suspected, BRCA1 and BRCA2 testing is recommended.
Which patients should be tested for BRCA1 and BRCA2 mutations?
- Breast cancer diagnosed at age 50 or younger
- Ovarian cancer at any age
- Multiple primary breast cancers either in the same breast or opposite breasts
- Both breast and ovarian cancer
- Triple-negative (hormone-receptor negative and HER2/neu? negative) breast cancer
- Pancreatic cancer with breast or ovarian cancer in the same individual or on the same side of the family
- Ashkenazi Jewish ancestry
- Two or more relatives with breast cancer, one under age 50
- Three or more relatives with breast cancer at any Age
Breast Cancer Tests
ARUP’s breast cancer experts and consultants are nationally and internationally recognized pathologists, subspecialty-qualified clinicians, and board-certified clinical scientists.
ARUP Consult® is a laboratory test selection support tool with more than 2,000 lab tests categorized into disease-related topics and algorithms. ARUP Consult—Breast Cancer
Video lectures on testing and test utilization
- Risk Mitigation in Breast Predictive Factor Testing
- Breast Predictive Factor Update
- Atypical Lesions: To Excise or Not To Excise?
- Molecular Testing in Breast Cancer: An Oncologist’s Perspectivea by Adam Cohen, MD
- Updates in Margin Status and Lymph Node Dissection by Leigh Neumayer, MD, MS, FACS
- Intraductal Proliferative Lesions of the Breast by Juan Rosai, MD
- Laboratory Testing for HER2 Status in Breast Cancer by Katherine Geiersbach, MD, FCAP, FACMG
- Surprise! Breast Tumors with Unexpected Final Pathology by Rachel E. Factor, MD, MHS
- Prognostic Gene Expression Tests for Early Stage Breast Cancer by Philip S. Bernard, MD
- Spindle Cell Lesions of the Breast by Erinn Downs-Kelly, DO, MS
- Spotlight on Testing: Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome by Hunter Best, PhD